A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development
Human tuberculosis remains a significant cause of mortality and morbidity throughout the world. The global economic impact of bovine TB is considerable. An effective vaccine would be the most cost-effective way to control both epidemics, particularly in emerging economies. TB vaccine research would...
Auteurs principaux: | Pepponi, I, Khatri, B, Tanner, R, Villarreal-Ramos, B, Vordermeier, M, McShane, H |
---|---|
Format: | Journal article |
Publié: |
Elsevier
2017
|
Documents similaires
-
The cross-species mycobacterial growth inhibition assay (MGIA) project 2010-2014
par: Brennan, M, et autres
Publié: (2017) -
Assessment of the reproducibility and inter-site transferability of the murine direct splenocyte mycobacterial growth inhibition assay (MGIA)
par: Tanner, R, et autres
Publié: (2021) -
The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells
par: Tanner, R, et autres
Publié: (2021) -
Development of mycobacterial growth inhibition assays for the early evaluation and gating of novel TB vaccine candidates
par: Tanner, R
Publié: (2015) -
Demonstrating the utility of the ex vivo murine mycobacterial growth inhibition assay (MGIA) for high-throughput screening of tuberculosis vaccine candidates against multiple Mycobacterium tuberculosis complex strains
par: Painter, H, et autres
Publié: (2024)